Cardiovascular Research

 
Stock Quotes for Cardiovascular Research top ^
  • Industry: Medical Devices
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Speculative Growth
Sign-up for csii investment picks
  • Industry: Medical Devices
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Speculative Growth
Sign-up for csii investment picks

 
News Articles for Cardiovascular Research top ^
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G021800-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/9/15/11G021800/amarin-1279518830220.jpg BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - September 16, 2014) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today its continued commitment to completing the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) cardiovascular outcomes study.
Sign-up for Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study investment picks
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), announced that the first seven patients in Japan have been enrolled in its Coronary Orbital Atherectomy System Trial (COAST) study.
Sign-up for Cardiovascular Systems Enrolls First Seven Patients in Japan for Coast Study investment picks
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), announced that it has completed enrollment in Japan for its Coronary Orbital Atherectomy System Trial (COAST) study.
Sign-up for Cardiovascular Systems Completes Coast Study Enrollment in Japan investment picks
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) today announced that its chairman of the board, Glen D.
Sign-up for Cardiovascular Systems, Inc.’s Board Chair to Retire investment picks
Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII) will host a live webcast of its fiscal 2015 first-quarter conference call on Wednesday, October 29, 2014, at 3:45 p.m. CT (4:45 p.m. ET). David Martin, President and Chief Executive Officer, and Larry Betterley, Chief Financial Officer, will discuss the company’s results for its fiscal first quarter ended September 30, 2014, and its financial outlook.
Sign-up for Cardiovascular Systems to Webcast Fiscal 2015 First-Quarter Earnings Conference Call Wednesday, October 29 investment picks
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), today announced that it has received CE (Conformité Européenne) Mark for its Stealth 360º Orbital Atherectomy System (OAS). Stealth 360º is a percutaneous OAS that is indicated to treat patients who suffer from peripheral arterial disease (PAD). “Securing CE Mark for Stealth 360º greatly expands our market opportunity and is an important milestone toward benefiting patients in Europe suffering from PAD—especially those with critical limb ischemia, (CLI) who have been underserved by other treatment options,” said David L.
Sign-up for Cardiovascular Systems Receives CE Mark for Stealth 360® Peripheral Orbital Atherectomy System investment picks
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial results for its fiscal first quarter ended September 30, 2014.
Sign-up for Cardiovascular Systems Reports Fiscal 2015 First-Quarter Financial Results investment picks
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced charitable donations totaling more than $1 million to be granted between 2014 and 2016 to seven nonprofit organizations that support patients with cardiovascular disease.
Sign-up for Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints.
Sign-up for VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Cardiovascular Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Cardinal Health  |  Next: Care Business